PMID- 32676425
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2223-4691 (Print)
IS  - 2223-4691 (Electronic)
IS  - 2223-4683 (Linking)
VI  - 9
IP  - 3
DP  - 2020 Jun
TI  - Role of application of tadalafil 5 mg once-daily (>/=6 months) in men with erectile 
      dysfunction from six randomized controlled trials.
PG  - 1405-1414
LID - 10.21037/tau-19-809 [doi]
AB  - This meta-analysis was performed to assess the efficacy and safety of taking 
      tadalafil 5 mg once-daily for at least 6 months in the treatment of erectile 
      dysfunction (ED). Based on databases: MEDLINE, EMBASE and Cochrane Controlled 
      Trials Register, this analysis was performed to collect randomized controlled 
      trials (RCTs) of tadalafil 5mg once-daily in treating ED over 6 months. Reviewers 
      also investigated the references of each literature. The meta-analysis covered a 
      total of 1,596 patients in six RCTs. The tadalafil group performed a better 
      effect in terms of the international index of erectile function-erectile function 
      (IIEF) domain (P=0.005) for the treatment of ED compared with the placebo group. 
      Safety assessments including discontinuations due to adverse events (AEs) 
      (P=0.31) and treatment-emergent AEs (P=0.06) indicated that the tadalafil group 
      had a better tolerate. The analysis elucidates that the dose of 5 mg per day of 
      tadalafil showed a good effect after the treatment of at least 6 months relative 
      to the control group with fewer side effects.
CI  - 2020 Translational Andrology and Urology. All rights reserved.
FAU - Ma, Jiajia
AU  - Ma J
AD  - Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao 
      University, Yantai, China.
FAU - Liu, Zi
AU  - Liu Z
AD  - Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao 
      University, Yantai, China.
AD  - Binzhou Medical University, Yantai, China.
FAU - Wu, Jitao
AU  - Wu J
AD  - Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao 
      University, Yantai, China.
FAU - Zhou, Zhongbao
AU  - Zhou Z
AD  - Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao 
      University, Yantai, China.
AD  - Binzhou Medical University, Yantai, China.
FAU - Zhang, Xuebao
AU  - Zhang X
AD  - Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao 
      University, Yantai, China.
FAU - Cui, Yuanshan
AU  - Cui Y
AD  - Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao 
      University, Yantai, China.
FAU - Lin, Chunhua
AU  - Lin C
AD  - Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao 
      University, Yantai, China.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - China
TA  - Transl Androl Urol
JT  - Translational andrology and urology
JID - 101581119
PMC - PMC7354289
OTO - NOTNLM
OT  - Randomized controlled trial
OT  - Tadalafil
OT  - erectile dysfunction (ED)
OT  - once-daily
COIS- Conflict of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at http://dx.doi.org/10.21037/tau-19-809). The authors have no 
      conflicts of interest to declare.
EDAT- 2020/07/18 06:00
MHDA- 2020/07/18 06:01
PMCR- 2020/06/01
CRDT- 2020/07/18 06:00
PHST- 2020/07/18 06:00 [entrez]
PHST- 2020/07/18 06:00 [pubmed]
PHST- 2020/07/18 06:01 [medline]
PHST- 2020/06/01 00:00 [pmc-release]
AID - tau-09-03-1405 [pii]
AID - 10.21037/tau-19-809 [doi]
PST - ppublish
SO  - Transl Androl Urol. 2020 Jun;9(3):1405-1414. doi: 10.21037/tau-19-809.